This activity is expired and is no longer available for CME credit.


Optimizing Efficacy and Adherence to Multiple Sclerosis Treatment: A Case Choice Initiative

Author(s)/Faculty: Edward J. Fox, MD PhD; Fred D. Lublin, MD, FAAN, FANA; Thomas P. Leist, MD, PhD; Megan R. Weigel, DNP, ARNP-C, MSCN
Release Date: 8/28/2014Expiration Date: 8/28/2015
Credit Type: CME / CNENumber of Credits: 0
Content Type: MultimediaProvider:
Multiple sclerosis (MS) is a chronic disease characterized by inflammation, axonal damage, and demyelination. Over 400,000 individuals in the United States and over 2.5 million worldwide are affected by MS. With no cure for MS, the goals of disease management include stopping disease relapses, delaying or preventing disability, and improving quality of life. For clinicians who manage patients with MS, it is important to keep up to date with the latest treatment advances, their benefits, limitations, and optimal use so that they can provide the best outcomes for their patients. This Case Choice initiative will look to optimize efficacy and adherence to MS treatment. Topics to be covered in the symposium include the mechanisms of action, the efficacy of currently available and emerging MS treatments, the evidence-based medicine about the safety and efficacy of early, effective evaluation and treatment of clinically-isolated syndrome in addition to MS, as well as how to tailor MS therapy to optimize and achieve adherence and compliance.